Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation
Infection and Drug Resistance · 2026-08 · Volume 19 · 1-47
DOI: 10.2147/idr.s619916 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection and Drug Resistance, 2026-08. Verfasst von Hamdi Al-Azzani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) continues to compromise the effectiveness of conventional antibacterial therapy, driving the development of therapeutic strategies that extend beyond direct antibiotic-mediated bacterial killing. Multidrug-resistant (MDR) pathogens evade treatment through diverse mechanisms, including enzymatic drug inactivation, target modification, efflux pump overexpression, biofilm formation, and persisters development. AMR results in chronic and recurrent infections, prolonged hospitalization, increased healthcare costs, and elevated morbidity and mortality, underscoring the need for innovative therapeutic approaches that target both the pathogen and the host. To bridge the dynamic interplay between bacterial pathogens and the host immune system with emerging therapeutic innovations, this narrative review first examines the biological mechanisms underlying bacterial resistance. It then explores therapeutic strategies beyond conventional antibiotics, providing an overview of current approaches and their limitations, including drug repurposing, bacteriophage therapy, and CRISPR-Cas technology. The review subsequently focuses on antibacterial immunotherapy, discussing a broad range of emerging approaches, including probiotics, monoclonal antibodies, cell-based therapies, host-directed therapies, aptamers, nanotechnology-based platforms, cytokine-based therapies, and antimicrobial peptides. An integrated overview of preclinical evidence, clinical studies, and FDA-approved therapies is presented to assess the translational potential of immunotherapy strategies in combating AMR. Scientific, regulatory, manufacturing, and implementation challenges that influence their successful translation into clinical practice are discussed throughout. By integrating the biological basis of host-pathogen interactions with emerging antibacterial therapeutics and their translational development, this review provides a comprehensive framework for evaluating innovative strategies against antimicrobial resistance. In contrast to modality-focused reviews, it offers a unified perspective that highlights the complementary roles of pathogen-targeted and host-directed interventions and identifies future opportunities to improve the prevention and management of multidrug-resistant bacterial infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- Quzhou People's Hospital (Quzhou Hospital Affiliated to Wenzhou Medical University), Quzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Hamdi Al-Azzani, Musaed Hamood Al-Subari
Zitieren
APA
Al-Azzani, H., Aliouat, H., Cheng, H., Dagah, O. M. A., Al-Subari, M. H., Zhou, W., & Wu, S. (2026). Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation. Infection and Drug Resistance, Volume 19, 1-47. https://doi.org/10.2147/idr.s619916
Vancouver
Al-Azzani H, Aliouat H, Cheng H, Dagah OMA, Al-Subari MH, Zhou W, et al. Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation. Infection and Drug Resistance. 2026;Volume 19:1-47. doi:10.2147/idr.s619916
BibTeX
@article{AlAzzani2026,
author = {Al-Azzani, Hamdi and Aliouat, Hanane and Cheng, Hongshi and Dagah, Omer M A and Al-Subari, Musaed Hamood and Zhou, Wenhu and Wu, Shugen},
title = {Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--47},
doi = {10.2147/idr.s619916}
}
EUVIMED